Neoadjuvant therapy with trastuzumab rezetecan and toripalimab for HR+/HER2-low breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a combination of two drugs (trastuzumab rezetecan and toripalimab) given before surgery to treat a specific type of breast cancer that is hormone-receptor-positive and HER2-low. It aims to see if this treatment can improve outcomes for patients who have not had prior cancer treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 70 years old.
- Your breast cancer has not spread to distant parts of the body (stage I to III) and is of a certain size and lymph node involvement (T1cN1-2M0 or T2-3N0-2M0).
- Your cancer is hormone-receptor-positive (HR+) and HER2-low (IHC 1+ or 2+ without gene amplification).
- You have not received any prior cancer treatment (no chemotherapy, radiation, or surgery for this cancer).
- Your overall health is good (ECOG performance status 0 or 1) and your major organs are working well enough.
- You are willing to use effective birth control during treatment and for 6 months after your last dose, and you agree to follow the study plan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a sequence of three drugs: first trastuzumab rezetecan (a targeted therapy), then a CDK4/6 inhibitor plus hormone therapy. It's for people with a type of breast cancer called HR-positive, HER2-low or ultra-low that has spread or come back and has already progressed on a CDK4/6 inhibitor and hormone therapy.
This trial tests a combination of two drugs, trastuzumab deruxtecan (SHR-A1811) and pertuzumab, given before surgery to shrink HER2-positive breast cancer. It is for women with stage II or III breast cancer who have not yet had treatment and are in good overall health.
This trial tests a new combination of two drugs—trastuzumab, a standard targeted therapy, and retifanlimab, an immunotherapy—for people with early-stage HER2-positive breast cancer. The goal is to see if adding immunotherapy before surgery can improve outcomes.
This trial tests a combination of two targeted therapies given before surgery to shrink HER2-positive breast cancer tumors. The goal is to see if this approach is safe and effective for early-stage breast cancer.
This trial tests different combinations of targeted therapy and chemotherapy before surgery for HER2-positive breast cancer. It uses a special PET scan to see how well the treatment is working and to help choose the best treatment plan for each person.
This trial tests a new antibody-drug combination (trastuzumab rezetecan, also called T-DXd) for patients with HER2-positive breast cancer whose tumor did not fully disappear after initial chemotherapy. The goal is to see if this drug can reduce the risk of cancer coming back.
Hear when a new HR Positive/HER2 Low Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.